Profile data is unavailable for this security.
About the company
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
- Revenue in USD (TTM)84.39m
- Net income in USD35.33m
- Incorporated2014
- Employees59.00
- LocationZevra Therapeutics Inc1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION 34747United StatesUSA
- Phone+1 (321) 939-3416
- Fax+1 (302) 636-5454
- Websitehttps://zevra.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elite Pharmaceuticals Inc | 140.12m | 43.41m | 414.11m | 68.00 | 9.94 | 5.14 | 9.20 | 2.96 | 0.0387 | 0.0387 | 0.1268 | 0.0748 | 1.29 | 3.03 | 4.18 | 2,060,564.00 | 39.98 | 13.18 | 45.86 | 16.01 | 51.06 | 47.19 | 30.98 | 13.97 | 5.44 | -- | 0.0517 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 427.16m | 120.00 | -- | 3.37 | -- | 6.38 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| SIGA Technologies Inc | 172.25m | 74.47m | 445.42m | 46.00 | 6.01 | 2.19 | 5.93 | 2.59 | 1.03 | 1.03 | 2.40 | 2.84 | 0.8069 | 0.7425 | 23.63 | 3,744,558.00 | 34.88 | 27.72 | 39.21 | 33.36 | 76.29 | 86.06 | 43.23 | 44.28 | 7.24 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Invivyd Inc | 50.04m | -59.86m | 456.82m | 99.00 | -- | 3.73 | -- | 9.13 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 461.80m | 900.00 | 6.89 | 0.807 | 2.65 | 0.5854 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 467.97m | 31.00 | -- | 20.24 | -- | 6.66 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 501.61m | 59.00 | 15.08 | 3.76 | 12.34 | 5.94 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 502.65m | 142.00 | -- | -- | -- | 11.58 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
| CorMedix Inc | 214.30m | 162.50m | 544.43m | 64.00 | 3.37 | 1.45 | 3.26 | 2.54 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Ironwood Pharmaceuticals, Inc. | 296.15m | 24.02m | 593.53m | 100.00 | 33.76 | -- | 22.92 | 2.00 | 0.1078 | 0.1078 | 1.86 | -1.61 | 0.792 | -- | 4.60 | 2,961,510.00 | 6.42 | -8.59 | 10.29 | -10.50 | -- | -- | 8.11 | -15.83 | -- | 4.14 | 1.81 | -- | -15.72 | -5.33 | 2,629.21 | -25.72 | -55.00 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 599.36m | 162.00 | 5.35 | 5.09 | 5.18 | 2.12 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 658.08m | 136.00 | -- | 6.63 | -- | 78.50 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Zevra Therapeutics Inc's reporting currency: US Dollar USD
36.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.13m | 7.34% |
| Woodline Partners LPas of 31 Dec 2025 | 3.45m | 6.13% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.90m | 5.15% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 2.29m | 4.07% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 1.77m | 3.15% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.48m | 2.63% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.34m | 2.38% |
| Millennium Management LLCas of 31 Dec 2025 | 1.13m | 2.02% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.09m | 1.94% |
| Legal & General Investment Management Ltd.as of 31 Dec 2025 | 1.09m | 1.94% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
